Funding for this research was provided by:
Novartis Oncology (EVA-12158)
Text and Data Mining valid from 2018-07-13
Received: 30 August 2017
Accepted: 6 June 2018
First Online: 13 July 2018
Ethics approval and consent to participate
: Institutional review board approval of the study protocol was obtained from Ethical & Independent Review Services (Independence, MO).
: The study sponsor was involved in the design of the study, interpretation of the data, and preparation, review, and approval of the manuscript. Anne Rentz and Anne Skalicky are employed by Evidera, which provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. As Evidera employees, they work with a variety of companies and organizations and are expressly prohibited from receiving any payment or honoraria directly from these organizations for services rendered. Drs. Liu and Said are employees of Novartis. Dr. Prestifilippo was an employee of Novartis at the time of the study; she has since retired. Dr. Dunn receives research support from Eli Lilly. Dr. Wheless is currently a consultant for Pfizer, Lundbeck, Cyberonics, Eisai, Sunovion, Supernus, and Upsher-Smith; he is part of a speaker’s bureau for Lundbeck, Questcor, Cyberonics, Eisai, and Supernus. He has received research grants from the NIH, Shainberg Foundation, GSK, Cyberonics, Eisai, Upsher-Smith, and Novartis. Ms. Nakagawa is employed by the Tuberous Sclerosis Alliance.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.